Genetically Engineered Pseudomonas Screening for Antibiotic Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pseudomonas aeruginosa is a multidrug-resistant opportunistic pathogen that causes severe infections, and current treatments lack effective mechanisms to inhibit its growth due to widespread antibiotic resistance.
Innovation Solution
The development of genetically engineered P. aeruginosa strains that are recA deficient and express pyocin genes, which can be stimulated by certain agents to increase pyocin production and sensitivity to antibiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat P. aeruginosa infections, then treatment options are limited, but antibiotic resistance mechanisms are widespread and treatment effectiveness is reduced
Solution Approach 1:
The patent divides the treatment approach into two distinct components: (1) pyocin production system using genetically engineered bacteria that express bacteriocins, and (2) antibiotic sensitization through RecA pathway inhibition. This segmentation allows each component to address specific aspects of the resistance problem independently, with pyocins providing direct antimicrobial activity and the sensitization approach restoring antibiotic efficacy against resistant strains.
Solution Approach 2:
The patent introduces genetically engineered P. aeruginosa strains as intermediaries that produce pyocins to kill target bacteria. These engineered strains act as living delivery systems that selectively produce bacteriocins against specific P. aeruginosa strains while sparing other bacteria. Additionally, RecA pathway inhibitors serve as intermediaries that sensitize resistant bacteria to antibiotics by blocking their DNA repair mechanisms.
2Reliability
If pyocin production is increased to enhance bactericidal effect, then sensitivity to antibiotics is improved, but the complexity of the treatment system increases
Solution Approach 1:
The patent employs genetically engineered P. aeruginosa strains that autonomously produce pyocins in response to specific stimuli. These engineered bacteria serve as self-regulating therapeutic agents that activate pyocin production only under appropriate conditions (such as detection of target bacteria or specific environmental cues), eliminating the need for external control systems and simplifying the overall treatment delivery mechanism.
Data Source
AI summary
Methods of screening for anti-pseudomonal compositions are disclosed that utilize a genetically engineered P. aeruginosa strain that is recA deficient and comprises a transcriptional reporter joined to at least a portion of a promoter for at least one gene of a pyocin gene cluster. The methods identify agents that stimulate pyocin expression in a RecA-independent manner. Also disclosed are agents identified by said methods, along with methods of producing and using same.